Th e impact of late percutaneous coronary intervention (PCI) in the patients after acute myocardial infarction (AMI) on long term mortality remains to be established. At currently, thrombolysis is accepted as standard therapy when PCI is not immediately available. However, PCI is often performed in stable patients with AMI who are/are not received thrombolysis . We performed the trial that enrolled myocardial infarction patients treated with thrombolysis, late PCI and medically to assess the potential benefi ts of delayed PCI. We follow up  consecutive patients after AMI one year. Th e patients are divided in two groups; fi rst group- patients who received reperfusion ( patients received only thrombolysis,  patients received thrombolysis and PCI - days after thrombolysis and  patients underwent only PCI after - days) and second group- patients medically treated. One year mortality was  in the reperfusion group (/) and , in the medical group (/) (p=,). Th ere were not signifi cant diff erences between groups about other end points-reinfarctus, coronary artery bypass surgery and PCI performed later after discharge. Th e major predictors of one year mortality were ages (p<,) and ejection fraction (p=,). Also, therapy with beta-blockers (p=,), statins (p=,) and ACE-inhibitors (p=,) was associated with better survival. Delayed PCI performed - days after AMI in the patients who underwent thrombolysis or those did not improves outcome at long-term follow-up
Introduction
Many studies were demonstrated lowering of mortality after acute myocardial infarction (AMI) in the patients who were treated by thrombolysis shortly after AIM (during hospitalization or -days after AIM) () . The salvaging of a jeopardized myocardium, patency of the infarct-related artery, microcirculatory perfusion, and myocytes preservation is consistent with the benefits achieved by reperfusion treatment () . However, meta-analysis of the long-term benefits of intravenous thrombolytic therapy in more than  patients participating in placebo-controlled trials shows that the risk of death after  month is equal in survivors of an AIM whether or not thrombolytic therapy was given irrespective of the time this treatment was started (based on data from the FTT Collaborative Group) () . Th e GUSTO (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries ) trial among the patients treated with diff erent thrombolytic agents showed fl ow through the infarctrelated artery was normal [Th rombolysis In Myocardial Infarction (TIMI) fl ow grade ] in around  percent of them () . Th e associations between patency of the infarct-related artery, better preservation of ventricular function, and improved survival after thrombolytic therapy for AIM suggests that only complete early reperfusion is associated with a reduced in-hospital mortality rate whereas patients with partial perfusion (TIMI grade ) have a short-term prognosis similar to that of patients with persistently occluded infarct vessels () . Also, myocardial contrast echocardiography (MCE) demonstrates that angiographically reflow cannot be used as an indicator of successful myocardial reperfusion in AMI patients (inadequate tissue reperfusion-"no refl ow" phenomenon) () . Other possible explanation may be higher incidence of rethrombosis and reinfarction in patients who received thrombolytic therapy after hospital discharge () . However, other studies demonstrated that successful reperfusion and myocardial salvage produce signifi cant mortality benefi ts that are amplifi ed beyond the initial  days () . Alternative treatment options of thrombolysis for coronary reperfusion in AIM is percutaneous coronary intervention (PCI). Th e DANAMI- trial showed that in patients with ST-elevation myocardial infarction (STEMI), a strategy of inter-hospital transfer for primary angioplasty was superior to on-site fi brinolysis at  days follow-up and the benefi t of transfer for primary angioplasty based on the composite endpoint was sustained after  years () . Also, a quantitative review of  randomised trials demonstrated that patients treated by PCI had a signifi cantly reduced likelihood of death, non-fatal reinfarction or stroke than those seen with thrombolytic therapy during long-term follow-up and whether or not the patient was transferred for primary PCI () . In many developed countries, it is diffi cult to off er primary angioplasty to more than  to  of eligible patients () . Th ere are few studies comparing PCI with thrombolysis followed PCI. The nationwide study in France included  centres and  patients over a -month period with -year follow-up was to assess outcomes in patients with AIM, with emphasis on comparing a pharmacoinvasive strategy (thrombolysis followed by routine angiography) with primary PCI (PPCI) concluded that a pharmacoinvasive strategy that combines thrombolysis with a liberal use of PCI yields early and -year survival rates that are comparable to those of PPCI () . Th e meta-analysis of randomized trials comparing PCI of the infarctrelated artery (> h to  days) with medical therapy in patients randomized > h after AMI showed a benefits of late PCI associated with significant improvements in cardiac function and survival () . Current data support the strategy of immediate PCI after lytics than waiting for rescue PCI if lysis is non-eff ective () . However, primary PCI is not off ered at  of United States hospitals, and less in many other countries () . The objective of this study was to investigate impact of both repefusion therapy-fibrinolytic and late PCI on one-year prognosis in the patients with AIM.
Methodology and Patients
The  consecutive patients who were hospitalized during one year-from June,  to June,  with fi rst AMI were followed-up one-year after discharge. Reperfusion therapy received  patients (group l) - thrombolysis ( only thrombolysis and  PCI after thrombolysis ) and  were performed PCI. PCI was performed  to  days after AIM. Th e  patients were not eligible for thrombolytic therapy and did not performed PCI (group ). Echocardiography (EHO) was performed at apparatus Philips HD  - days from AMI. Troponine I was analyzed at apparatus Axsym (Аbbott), creatine kinase and cholesterol at apparatus Beckman Sych . Coronarography was performed by usual techincs - days from AMI.
Statistical analysis
All analyzes were performed using SPSS . statistical software. Chi-square were used to determine the significance of the differences between mean values of baseline characteristics of the patients of the both 
Results

Baseline Characteristics
Th e  consecutive patients with fi rst AMI were follow-up one year after discharge from hospital. Of them,  patients () received thrombolysis (  only thrombolysis and  patients PCI after - days of thrombolysis) and only angioplasty  patients (). Th ese  patients with reperfusion therapy represent group l and others  patients group . The baseline characteristics of the both groups are presented in Table l . The patients of group l were younger (, ±, vs. ,±,, p<,) and men were treated with reperfusion therapy (RT) frequently than women ( vs. , p<,).The cardiac biomarkers, creatine kinase and troponins I were elevated signifi cantly higher among the patients with RT (, vs. ,, p<, and , vs. ,, p<,). Th e patients treated with RT had frequently anterolateral Q wave AIM ( /- vs. /- respectively, p<,). A part RT other therapy was not been diff erent except furosemid which were been used less frequently among the patients treated with RT (/- vs. /-, p<,).
Results of Coronary Angiography, Angioplasty and Echocardiography
Cardiac catheterization was carried out in the  patients with RT (/-,) ant in  patients without RF (/-,). Among  patients who received RT  had occluded infarct arteries and  patients of these without RF (/-, vs. /-, respectively). One occluded artery was reopened in the patients who were treated with RT. PCI was performed in  patients: the  patients with previously received thrombolysis and in the  patients without thrombolysis.
The patients who received thrombolysis (early reperfusion) had signifi cantly higher EF than those who did not (, ±, vs. ,±,, respectively, p=, ) ( Table  ) . There was strongly correlation of concentration curve of Troponin I (Tn I) with low EF ≤ area under the ROC (receiver operating characteristic) curve ,,  CI , -,, p< ,.
Mortality
During follow-up,  patients (/-) in RT group died versus  (/-,) in without RT group.
Oneyear survival demonstrated by Kaplan Meier survival curves was much better (log rank -,, p=,) in the patients who underwent reperfusion ( Figure . ). In the subgroup of  patients who were performed PCI all patients were survived, while  patients died among the  patients who were treated only with thrombolysis One-year mortality risk modelling was performed with Cox regression model analysis which is identifi ed age as the signifi cant factor associated with increased mortality ( p<,). Another factor infl uencing one-year mortality was EF (p=,). Also, Cox regression using For-AMI-acute myocardial infarction, ACE-angiotensin converting enzyme ward Stepwise selection method demonstrated among variables related to therapy that beta-blockers (p=,), statins ( p=,) and ACE-inhibitors (p=,) were associated significantly to the survival time.
Reinfarction had  patients in RT group (OD ,,  CI , to ,) and  patients in without RT group( OD-l,,  CI , to ,). In the followup period  patients underwent PCI among the patients with RT (/-,) and  patients who did not RT (/-,). Coronary artery bypass graft surgery (CABG) after hospital discharge was performed in the  patients with RT (/-,) and in the  patients among patients without RT (/-,).
Discussion
The principle aim for treatment of AMI is restoring coronary blood flow and reperfusing cardiac tissue achieving with thrombolysis or primary PCI. A prospective survey performed in Europe to examine adherence to current guidelines for ST elevation acute coronary syndromes the use of fibrinolytic therapy was , and , of primary PCI () . In this study thrombolysis received   of the patients, , PCI of them and   late PCI only because availability of our centre does not off er  h/ days primary PCI service. Baseline characteristics demonstrated that the patients with RT had frequently anterior AIM, higher peak concentration of cardiospecific enzymes that signifi es larger nekrosis of myocardium, but these patients were used much less diuretics suggesting good influence of reperfusion therapy on cardiac function.. Th at is also true because EF of left ventricle was statistically better in the patients who received thrombolysis than those who did not (,±, vs. ,±,, p=. ).
On the contrary to early reperfusion which reduce myocardial infarct size late reperfusion favourably affect infarct healing limit infarct expansion and limit LV remodelling () . Th e patients with RT had much better survival than the patients without RF (p=,). Th e mechanisms proposed for benefit of late reperfusion which is known to reduce both cardiac remodelling and mortality and mitigates postinfarction remodelling is fi nding of granulation tissue cell proliferation which was increased to a greater degree in the patients who performed reperfusion () . In the fi rst large study which compare conservative and interventional therapy in patients who were subacute phase after AIM and single vessel disease overall mortality at follow up of  months was low, indicating a  risk per year but reduction in mortality from  to  with interventional therapy () . Also, a prospective cohort of revascularisation patients within  days after AIM admitted to the coronary care units of  Swedish hospitals between  and  was obtained at  year mortality was , in the conservative group and ,) in the early revascularisation group () . In our study Cox regression model analysis is identifi ed ages (p<,), EF (p=,) and among variables related to therapy that beta-blockers (p=,), statins ( p=,) and ACE-inhibitors (p=,) as the signifi cant factors associated with increased mortality. In other study which was examined long-term (three years) prognosis in patients with AMI who underwent acute revascularization therapy advancing age was associated with increased mortality, also () . Th e long term survival benefi t in that study was demonstrated with more often the use of beta-blockers and ACE inhibitors in the patients with reperfusion therapy over three years period suggesting a better prevention of reocclusion and reinfarction and better preserved left ventricular function in patients treated with reperfusion therapy ().
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